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Abstract:
Diabetes is associated with liver disease progression and increased hepatocellular carcinoma risk, but factors associated with diabetes in patients with chronic hepatitis B virus (HBV) infection in North America are unknown. We aimed to determine factors predictive of diabetes and impaired fasting glucose (IFG) in a large HBV-infected multi-ethnic cohort. Adults with chronic HBV not receiving antiviral therapy were enrolled from 21 centers in North America. Diabetes was defined by history/medication use or fasting glucose ≥126 mg/dL and IFG as fasting glucose 100-125 mg/dL. Of 882 patients included 47.2% were female, 71.3% Asian, 83.7% foreign-born, median age was 44 years and median BMI 24.3 Kg/m 2 . In this cohort, 26.0% were HBeAgpositive, 43.9% had HBV DNA ≥20,000 IU/mL, and 26.7% ALT ≥2xULN (≥40 U/L women, ≥60 U/L men).
Overall, 12.5% had diabetes and 7.8% IFG. The combined prevalence of diabetes or IFG was highest among blacks (36.7%) and those either born in US/Canada or foreign-born with migration >20 years ago (25.5%).
Obesity (OR 2.13), hyperlipidemia (OR 4.13), hypertension (OR 3.67), high ALT level (OR 1.86), and family history of diabetes (OR 3.43) were associated with diabetes. Factors associated with IFG were obesity (OR 4.13) and hypertension (OR 3.27) but also HBeAg-positivity (OR 0.39). Recent migration was negatively associated with diabetes among non-Asians (OR 0.30). Conclusions: Diabetes is more prevalent in HBVinfected North American adults than the general population and is associated with known metabolic risk factors and liver damage as determined by ALT levels. Among the foreign-born, longer duration of North America residence predicted diabetes risk in non-Asians. These results highlight the opportunities for interventions to prevent diabetes especially among at-risk ethnic groups with HBV. Diabetes and prediabetes areis prevalent in North American adults with chronic HBV and are is associated with known metabolic risk factors and ALT but not HBV DNA. Among the foreign-born, longer duration of North America residence predicted diabetes risk in non-Asians. These results highlight the opportunities for interventions to prevent diabetes especially among at-risk ethnic groups with HBV.
Introduction
An estimated 1.25 million individuals in the United States (US) are chronically infected with hepatitis B virus (HBV) and approximately 43,000 new infections occur annually (1, 2) . Recent data suggest that the number of foreign born individuals with chronic HBV living in the US may be greater than previously reported and the actual number of persons with chronic HBV infection may be as high as 2.2 million (3). Chronic HBV infection is associated with a risk of progression to cirrhosis, liver failure, and the development of hepatocellular carcinoma (HCC) (4) . As such, HBV represents a significant public health burden in North America. The majority of HBV-infected individuals in North America are foreign born and have emigrated from endemic regions such as Asia and the Pacific Islands and Africa (3) . A growing body of evidence indicates that the observed rise in the incidence of obesity in North America and its associated syndromes, especially diabetes and metabolic syndrome, may contribute to the negative consequence of HBV disease (5, 6) . For example, these conditions have been associated with increased liver inflammation (7), progression of liver fibrosis (8) (9) (10) , and increased mortality in the setting of HBV infection (11) . Persons with diabetes also have higher prevalence of hepatitis B than the general population and HBV testing and vaccination in susceptible individuals is recommended in diabetics (12). Moreover, diabetes is independently associated with an approximately 2-fold increase in risk of liver cancer compared to non-diabetics and this risk increases by 100-fold in the presence of combined diabetes and obesity among those infected with hepatitis B or C infection (13). This suggests viral and metabolic effect may accelerate the progression of liver disease and increase liver cancer risk. Therefore, prevention and control of diabetes may contribute to improving HBV disease outcomes.
Considering the epidemic of diabetes, appropriate screening and treatment of prediabetic states, such as impaired fasting glucose (IFG) has importance in the control of diabetes. Early identification of pre-diabetes and intervention with lifestyle modification and/or pharmacologic therapy is currently recommended (14) . IFG is exceedingly prevalent in North America, affecting about 37% of adults aged 20 years and older (15). The limited information to date, predominantly from HBV endemic regions, shows that the prevalence of diabetes among persons with chronic HBV infection varies among countries and ranges from 6-14% (16) (17) (18) (19) . In a study 
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7 using data from the National Health and Nutrition Examination Survey III where only about 0.4% of the 15,866 subjects had chronic hepatitis B, prevalence of diabetes was reported as 7.0 ± 4.8% (11) . There is even less information on the prevalence of prediabetes. In one study approximately 26% of Nigerians with chronic HBV had IFG (20) . The reported factors associated with abnormalities of glucose metabolism have included both host and viral factors (16, 20, 21) . These studies however may not be applicable to the North American HBVinfected population due to greater ethnic diversity as well as differences in global prevalence of obesity and metabolic abnormalities.
Given the paucity of data and the high prevalence of metabolic abnormalities in North America, we assessed the prevalence of diabetes and IFG as well as the relationship between host and viral factors and abnormalities of glucose metabolism in a large racially diverse North American cohort with chronic HBV infection.
Methods:
This is a cross-sectional study of patients enrolled within the Diseases, and comprises 21 adult liver centers in the United States and in Toronto, Canada. Details of the HBRN and the adult cohort study had been described previously (22) . The HBRN adult cohort study enrolled HBsAg-positive persons greater than 18 years of age who did not have a history of hepatic decompensation, HCC, solid organ or bone marrow transplantation or HIV coinfection, and who were not receiving antiviral therapy. For this study, participants with acute HBV infection, who were pregnant, and did not have known baseline diabetes status or fasting glucose values within 6 months of the baseline visit were excluded.
American Diabetes Association recommends diagnosis of diabetes or prediabetes based on hemoglobin A1C or plasma glucose -fasting levels or 2-h value after a 75 g oral glucose tolerance test (23). Hemoglobin A1C and oral glucose tolerance test were not performed in the HBRN Cohort Study. Type 2 diabetes (referred to as diabetes throughout) was therefore defined as a known history of diabetes or current use of anti-diabetic 
Statistical Analysis:
Descriptive statistics included median and range and mean ± standard deviation (SD) as appropriate. represented the records with missing values (29) . Through this technique, all records were kept in the regression models. SAS version 9.3 was used for all analyses.
Results:
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Of the total of 1559 consecutive and non-pregnant patients with chronic HBV infection enrolled in the HBRN Adult Cohort Study during the study period, 677 patients with no known history of diabetes were excluded because of unavailable fasting glucose levels to ascertain diabetes or prediabetes status ( Figure 1 ). The remaining 882 were included in this study. Latino/other racial group 3.3% vs 4.3%, p=0.8).
Prevalence of diabetes and IFG
Overall, 110 patients (12.5%) had diabetes, 69 (7.8%) had IFG, and 703 (79.7%) had normal glucose levels.
Patients with normal glucose levels were significantly (all p<0.0001) younger, had smaller waist circumference, lower BMI as well as lower prevalence of hypertension and hyperlipidemia than those with glucose abnormalities (IFG or diabetes) (Supplemental Table 1 ). Among persons with glucose abnormalities, those with diabetes were significantly older (p=0.007) and had higher prevalence of hypertension (p=0.003), hyperlipidemia (p<0.001), and family history of diabetes (p<0.001) than those with IFG. (Figure 2 ). The prevalence of IFG was also highest among blacks (13.3%) and was nearly double that of other racial groups. The combined prevalence of diabetes or IFG was higher among those who were born in US/Canada or foreign born with more than 20 years of migration to US/Canada compared to those who were foreign born with a shorter duration of migration (25.5% vs 13.4%, p <0.0001). The prevalence of diabetes was also higher among those with significant liver fibrosis or cirrhosis defined as APRI score >1.5 (20.5% vs 11.5%, p=0.1) and those with elevated ALT levels (16.3% vs 10.5%, p=0.05) but these differences
were not statistically significant. Even after stratification by age, prevalence of glucose abnormalities was significantly higher in the groups with higher ALT levels (p=0.04) ( Figure 3A ). Although the overall rate of 
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10 diabetes was higher in HBeAg-negative than in HBeAg-positive patients (13.4% vs 7.8%), when stratified by age, the overall prevalence of glucose abnormalities (IFG versus diabetes versus normal glucose) in HBeAgpositive and HBeAg-negative patients was not different (p=0.47) ( Figure 3B ). Similar to observations in the general population, the prevalence of diabetes was lower in those with moderate alcohol consumption than those with a history of heavy or no alcohol intake (8.8% vs. 16.9% or 13.1%, respectively), although this did not reach statistical significance (p=0.5).
Relationship between host and HBV-related factors and abnormalities of glucose metabolism
In multivariable logistic regression models that controlled for age, gender, and race, patients with high ALT (≥2 This article is protected by copyright. All rights reserved. Table 3 .
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11 estimated 70% reduction in the odds of diabetes among non-Asians (OR 0.3, 95%CI 0.10-0.94, p=0.04)
Discussion:
Type 2 diabetes represents a major public health burden due to its rising prevalence worldwide (30) . Because patients with diabetes have higher prevalence of HBV infection, screening and treatment of prediabetes and diabetes are especially relevant in this population as impaired glucose metabolism has been shown to promote liver fibrosis (8) (9) (10) and to increase the risk of HCC (4). This study evaluated the prevalence of glucose abnormalities and the associated factors in a large cohort of multi-ethnic HBV-infected persons residing in the US and Canada. We demonstrated that nearly a quarter of this cohort had diabetes (13%) or prediabetes (8%).
Current estimates of prevalence of diabetes in US and Canadian adults are 9% and 8%, respectively(15) (31) and approximately 37% of the US population 20 years or older has IFG (15), suggesting that diabetes was more prevalent but IFG less prevalent in our HBV cohort compared to the general population. However, the racial/ethnic composition of the HBRN cohort is markedly different from that of the general population in the US or Canada. We also showed a significant association between liver damage as determined by ALT levels and diabetes in patients with chronic HBV infection, suggesting that lowering ALT levels with antiviral therapy or weight loss, as well as effective diabetes management may be potentially important means of decreasing the risk of liver disease progression in this population.
Prior studies have suggested that the inflammatory milieu associated with chronic viral infections may influence hepatic glucose sensitivity and increase insulin resistance (32) . Liver inflammation has also been shown to be a risk factor for prediabetes in the setting of hepatitis C infection (33) . The finding that serum ALT was associated with diabetes provides support for the hypothesis that active necroinflammation in the liver, whether HBV-related or not, predisposes to hyperglycemia, perhaps through oxidative or ER stress (34) . Alternatively, the elevated ALT among diabetics may reflect concurrent fatty liver, though liver biopsy or standardized imaging data was not available to confirm this diagnosis. In this cross-sectional analysis, we cannot discern what is cause and effect, but with longitudinal follow-up of this cohort, the contribution of HBV-related liver damage to diabetes/prediabetes risk can be studied and the impact of glucose abnormalities on liver disease progression can be evaluated.
While no viral specific factors were associated with diabetes, HBeAg status was negatively associated with IFG when controlling for age. The significance of this finding is unclear but the confidence interval around the estimate associated with HBeAg status was wide and reflects some degree of uncertainty about the estimated effect. HBV DNA levels were not independently associated with diabetes or IFG. These observations suggest that while HBV DNA levels are predictive of clinical outcomes such as hepatic cirrhosis or HCC (35, 36), they do not appear in and of themselves to be associated with development of diabetes or diabetes risk. Similarly, in a recent study of a large population-based Alaska Native cohort with over 20 years of follow-up, presence of HBV infection did not have an effect on diabetes development (21) . Instead, our results suggest that diabetes in more closely linked to host factors than to viral factors.
Not surprisingly, diabetes was more prevalent among older persons and those with other metabolic risk factors, specifically higher BMI and waist circumference, hypertension, dyslipidemia, and family history of diabetes. Indeed, the American Diabetes Association guidelines for prevention of type 2 diabetes recommends that patients with prediabetes be referred to an intensive diet and physical activity behavioral counselling program targeting loss of 7% body weight and metformin therapy may also be considered especially for those with BMI>35 kg/m 2 , aged<60 years, and prior history of gestational diabetes (23). Importantly, we also identified significant racial-ethnic differences in the prevalence of diabetes and prediabetes in the HBV population. The lowest prevalence was seen among Asians and highest among blacks. Overall, birth status or duration of migration on its own was not an independent predictor of diabetes or IFG. However, we found a strong association between duration of time in the US/Canada and risk of diabetes among foreign-born nonAsians, the majority of whom were of African origin. Duration of migration did not seem to significantly influence risk of diabetes in Asians most of whom were of Chinese origin. This finding is similar to some prior studies of Chinese Asian population that also did not show a significant influence of length of migration on Page 12 of 32
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13 diabetes risk (37) . This suggests that environmental influences (primarily dietary) may be contributing to higher diabetes risk among some foreign-born and predisposed populations but not others. While assimilation and migration duration among at-risk immigrant population has been shown to be associated with higher prevalence of diabetes (38) , this has not been consistently observed (39) . This is likely due to potential differences in acculturation and assimilation among different immigrant populations and the complexity of the relationship between immigration, acculturation, and adverse health outcomes.
There are recognized limitations of this study. As the racial and potentially age distribution of HBRN cohort is different from the general population in US and Canada, it is not possible to directly compare the prevalence of IFG/diabetes to the general population. Due to its cross-sectional nature, the temporal relationship between diabetes/prediabetes and the metabolic and viral factors could not be assessed. Indeed, the dynamic nature of chronic HBV infection with varying periods of high necroinflammatory activity that may influence diabetes risk over time, were not captured. Additionally, fibrosis stage was determined by indirect non-invasive tests (APRI) and may have underestimated the proportion of patients with cirrhosis, the latter a risk factor for diabetes/prediabetes. There are known limitations to either A1C or plasma glucose values to define diabetes/prediabetes and the definition used may impact their reported prevalence in populations studied. In the HBRN cohort study, oral glucose tolerance test or hemoglobin A1C was not performed and baseline fasting glucose level was used for diagnosis of IFG and previously undiagnosed diabetes. Use of A1C may result in potentially higher reported prevalence of prediabetes (40) but one-third fewer cases of undiagnosed diabetes compared to fasting plasma glucose criteria, while use of oral glucose tolerance test may diagnose more people with diabetes than A1C or fasting glucose cut points (23). The strengths of this study include the large sample size, diverse racial-ethnic population and detailed information on metabolic cofactors.
In summary, diabetes and prediabetes are prevalent among HBV-infected patients living in the US and Canada. Among the foreign-born HBV-infected population, who account for the majority of HBV infections in the US and Canada, we found duration of residence in the US/Canada to be a predictor of diabetes/ prediabetes risk but only among non-Asians. Importantly, in addition to known metabolic risk factors, diabetes is associated with elevated ALT but not HBV viral level in patients with chronic HBV infection. The results of 
14 our study provide a basis for education and interventions to prevent and better manage diabetes in HBVinfected patients. This is an important objective, since diabetes is expected to further increase the risk of HBVrelated cirrhosis and HCC. Moreover, our finding suggests a potential role for preventing diabetes through reduction in ALT and liver damage with antiviral therapy or preventing liver disease progression through diabetes management, weight loss, and reduction in liver damage. These hypotheses warrant further study.
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<0.0001
Gender (%) 0.03 
*P values are for all group comparison and P <0.05 (2-sided) is considered statistically significant.
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